CLINICAL TRIAL: USE OF TH9507 IN HIV INFECTED INDIVIDUALS WITH EXCESS ABDOMINAL

临床试验：TH9507 在腹部过大的 HIV 感染者中的使用

• 批准号: 7731261
• 负责人: STEVEN K. GRINSPOON
• 金额: $ 1.34万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731261
• 关键词: Abdomen; Adipose tissue; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dyslipidemias; Fatty acid glycerol esters; Funding; Grant; HIV; Individual; Institution; Lipids; Lipodystrophy; Outcome; Research; Research Personnel; Resources; Somatotropin; Somatotropin-Releasing Hormone; Source; TH9507; United States National Institutes of Health; Visceral; Week

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV lipodystrophy is characterized by excess visceral fat, dyslipidemia, and low growth hormone (GH) levels. TH9507 is a GH releasing factor that physiologically increases GH levels. A previous study of TH9507 resulted in decreases in visceral adipose tissue (VAT) and trunk fat, increases in lean body mass and lipid profile improvement, and was generally well-tolerated. This study is aimed at investigating the effects of TH9507 for 26 weeks and duration of these benefits. The primary outcome is reduction of VAT.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 HIV脂肪营养不良的特征是内脏脂肪过多、血脂异常和生长激素(GH)水平低下。TH9507是一种生长激素释放因子，生理性地增加生长激素水平。TH9507之前的一项研究表明，TH9507可以减少内脏脂肪组织(VAT)和躯干脂肪，增加瘦体重和改善血脂状况，总体耐受性良好。本研究旨在探讨TH9507治疗26周的疗效及其持续时间。主要结果是增值税的减少。